 Nuwellis

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Nuwellis reports revenue growth and margin improvement in Q1 2024

Nuwellis' Q1 2024 performance showed revenue growth driven by consumable utilization, improved margins, and reduced operating losses. Challenges in critical care revenue persist, but expense reductions and growth opportunities in pediatrics signal a positive outlook.

Nuwellis reports revenue growth and operational improvements in Q2 2024

Nuwellis (NUWE) showed improved financial performance in Q2 2024 with revenue growth and reduced operating loss, despite challenges in the pediatric segment.
The company's strengths lie in successful product launches, financial stability, and increasing market presence, while facing challenges in pediatric revenue and R&D expenses.
Opportunities for Nuwellis include leveraging positive momentum, expanding product adoption, and capitalizing on its strong financial position for future growth.

Nuwellis reports Q3 revenue decline but operational improvements signal growth

Nuwellis showed mixed financial performance in Q3 2024 with revenue decline but operational improvements and net income.
The company faces challenges in certain product categories but benefits from growth opportunities like increased reimbursement rates.
Strategic decisions like terminating agreements and raising funds position Nuwellis for future growth and market competitiveness.
Overall, Nuwellis is navigating a dynamic market landscape with a focus on product effectiveness and financial sustainability.

Nuwellis reports Q1 revenue growth, eyes strategic expansion opportunities

Nuwellis showed overall revenue growth driven by specific product segments despite challenges in Critical Care sales. The company's focus on key growth areas and strategic initiatives positions it well for future expansion. Opportunities in clinical trials, reimbursement coverage, and operational efficiency highlight Nuwellis' growth potential.

Nuwellis reports Q3 revenue decline but maintains financial stability

Nuwellis faced revenue decline and increased operating expenses in Q3 2025, impacting profitability. Despite challenges, the company showcased strengths in innovation, operational efficiency, and financial stability. Addressing cost management, revenue diversification, and market expansion present key opportunities for future growth. Overall, Nuwellis remains well-positioned with a strong product portfolio and a debt-free financial status.

Nuwellis reports Q4 revenue growth, eyes strategic expansion in 2026

Nuwellis' Q4 performance showed revenue growth and strong margins, reflecting operational improvements and strategic realignment efforts. While facing revenue challenges in 2025, the company's focus on operational efficiency, financial discipline, and liquidity management positions it well for future growth. Opportunities lie in expanding commercial performance, integrating acquisitions, and leveraging strengths to drive revenue growth and market expansion in 2026.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow